OncoLab Diagnostics aims to contribute substantially to enhancing survival time and quality of life of cancer patients and reducing cancer mortality. We will achive this by developing, manufacturing and marketing highly innovative and utmost precise cancer tests.
To achieve our goals we engage in research and development activities in close cooperation with renowned worldwide academia and industry partners. Oncolab Diagnostics is dedicated to research and development to find new means and technologies to diagnose cancer and to characterise its specific nature.
Circulating Tumour Cells
A new age of personalized cancer care begun with the introduction of “Liquid Biopsy”, a blood test detecting cancer in the circulation and providing a non-invasive picture of a patient’s cancer. It offers possible post-therapeutic surveillance of recurrence.
Blood biopsy diagnostics is a mix of high-tech technology and cutting edge medical procedures, and offers new ways for selection of the right drug for the right patient at the right time — all through a simple blood draw.
Just a blood sample is needed to see whether a person suffers from cancer or not. Also the information if a cancer patient is responding to a certain therapy or if an alternative treatment should be chosen, can been derived from a single blood sample.
The OncoLab team combines profound knowledge and expertise in tumour biology, oncology and international research projects. Besides the high scientific quality, the CEO of OncoLab has long-term experience in managing and operating diagnostics enterprises as well as in developing and marketing diagnostic tests.
OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Strasse 2, Objekt E
2700 Wiener Neustadt / Lower Austria
Phone: +43 (0)2622 / 32913